Risankizumab

Drug Profile

Risankizumab

Alternative Names: ABBV 066; BI-655066; Humanised IgG1 monoclonal antibody - Boehringer Ingelheim

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
  • Phase II Ankylosing spondylitis; Asthma; Crohn's disease; Psoriatic arthritis
  • Phase I Psoriasis

Most Recent Events

  • 24 Aug 2017 AbbVie plans a phase III trial for Plaque psoriasis (Treatment-naive) in Germany (NCT03255382)
  • 01 Aug 2017 Boehringer Ingelheim and AbbVie completes a phase II trial in Psoriatic arthritis in Finland, France, Germany, Japan, Netherlands, Poland, Spain, Taiwan, Czech Republic, Belgium, USA and Canada (SC) (NCT02719171)
  • 01 Aug 2017 Boehringer Ingelheim completes a phase III trial in Plaque psoriasis in USA, Canada, Australia, France, South Korea, Czech Republic, Germany and Japan (NCT02684370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top